CA-MAWI-DNA-TECHNOLOGIES
25.1.2021 15:02:12 CET | Business Wire | Press release
Mawi DNA Technologies’ iSWAB-Microbiome-EL sample collection technology enables BioTech Africa to implement and launch a new ultra-high throughput COVID-19 testing program. This breakthrough, in conjunction with the ProbeSure™ COVID-19 One Step RT-PCR Kit from 3CR Bioscience, is designed to scale up to a capacity of 200,000 tests per day.
“We are extremely proud and humbled to be part of South Africa’s fight against COVID-19 through BioTech Africa’s mass testing efforts,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies.
In addition, Dr. Jenny Leslie, COO of BioTech Africa, worked closely with Scilutions Labware and Hook Diagnostics to identify the best products and supplier partners who could provide reagents to streamline the testing workflow, but also scale to the projected numbers with minimal supply chain disruption.
“For the sample collection step, Mawi DNA Technologies’ iSWAB-Microbiome-EL (‘Extractionless’) product was chosen for its multiple benefits. This includes enabling direct PCR by removing the RNA extraction step along with extended room temperature stabilization of viral RNA. iSWAB technology also enables simple and efficient non-invasive self-collection, a key component of BioTech Africa’s testing strategy to encourage widespread compliance,” said Dr. Leslie. She added, “When used in tandem with the 3CR Bioscience ProbeSure™ kit, we can provide high throughput testing and faster sample-to-result turnaround time, while significantly reducing reagents, plastics and testing workflow footprint.”
“iSWAB room temperature sample collection and stabilization technology has been well validated in the field with millions of samples tested thus far,” said Dr. Bassam El-Fahmawi. He added that Mawi DNA was pleased to work with Scilutions Labware and Hook Diagnostics to deploy its products on a global scale to help alleviate the socioeconomic impact that COVID-19 brought on the world.
Hook Diagnostics CEO Simon Kratzat added, “Our mission at Hook Diagnostics is to enable affordable population scale testing. We are honored to make this a reality for BioTech Africa together with Mawi DNA, 3CR and Scilutions.”
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Its flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. iSWAB-Microbiome has gained worldwide acceptance as a superior collection technology for COVID-19 samples. Mawi DNA has expanded its offerings to include collection technologies for intact cells and whole blood. For more information, visit http://www.mawidna.com .
About BioTech Africa
BioTech Africa specializes in recombinant protein production and bioprocessing. Driven by the global requirement for improved in vitro diagnostics, its current range of highly purified recombinant proteins are used in the manufacture of diagnostic test kits for point of care rapid diagnostics and research institutions. BioTech Africa offers a variety of protein expression platforms along with a host of other protein services, including protein refolding and structural biology analysis. For more information, visit http://www.biotechafrica.com .
About Scilutions Labware
Scilutions is an innovative manufacturer of scientific products. Through collaboration with the academic, industrial and scientific communities, its manufacturing capabilities are aligned to ensure that the company is optimized to support critical biomedical operations. For more information, visit http://www.scilutionslabware.com .
About 3CR Bioscience
3CR Bioscience is a world-leading manufacturer of innovative PCR-based reagents. Primary products, PACE™ and ProbeSure™, are used in hundreds of institutions worldwide, from small academic labs to large multinational companies. 3CR has developed the ProbeSure™ COVID-19 One Step RT-PCR Kit which combines high sensitivity and specificity with low cost and has been designed for use in real-time or high-throughput endpoint processes. For more information visit https://3crbio.com/ .
About Hook Diagnostics
Hook Diagnostics is committed to making worldwide population-scale testing faster and more affordable using only the most high quality and cutting edge tools available. For more information, visit http://www.hookdx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005262/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom